A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets

NCT06680531 | Active Not Recruiting Phase 1

• 1 other identifier: YZJ-1139-1-14
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

Primary Objective： 1\) To evaluate the pharmacodynamic interaction between YZJ-1139 tablets and Escitalopram oxalate tablets in healthy subjects; 2) To evaluate the pharmacokinetic interaction between YZJ-1139 tablets and Escitalopram oxalate tablets in healthy subjects; To observe the safety of YZJ-1139 tablets taken together with Escitalopram oxalate tablets.

Conditions

Insomnia; Central Nervous System

Outcome Measures

Primary Outcomes (13)

• saccade eye movement test

  Saccadic eye movements were evaluated by using a computer-based electronystagmography system.To assess the change in scores for escitalopram oxalate tablets combined with YZJ-1139 tablets relative to YZJ-1139 tablets simulant and YZJ-1139 tablets.

  From Day 1 to Day 11

• body swing test

  Body swing test was measured with an apparatus, which integrates the amplitude of unidirectional body sway. To assess the change in scores for escitalopram oxalate tablets combined with YZJ-1139 tablets relative to YZJ-1139 tablets simulant and YZJ-1139 tablets.

  From Day 1 to Day 11

• selective reaction time test

  Subjects selected buttons in different directions according to Chinese character prompts on a computer screen,assess the change in scores for escitalopram oxalate tablets combined with YZJ-1139 tablets relative to YZJ-1139 tablets simulant and YZJ-1139 tablets.

  From Day 1 to Day 11

• number symbol conversion test

  Subjects click the corresponding number according to the corresponding relationship between the given symbol and the number. To assess the change in scores for escitalopram oxalate tablets combined with YZJ-1139 tablets relative to YZJ-1139 tablets simulant and YZJ-1139 tablets.

  From Day 1 to Day 11

• word memory test

  Subjects recall presented words at specific times.To assess the change in scores for escitalopram oxalate tablets combined with YZJ-1139 tablets relative to YZJ-1139 tablets simulant and YZJ-1139 tablets.

  From Day 1 to Day 11

• Maximum Observed Plasma Concentration (Cmax) of YZJ-1139

  Cmax is defined as the maximum concentration of drug.

  From Day 1 to Day 11

• Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC0-t) of YZJ-1139

  AUC0-t is defined as the concentration of drug from time zero to the last observable concentration.

  From Day 1 to Day 11

• Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of YZJ-1139

  AUC0-∞ is defined as the concentration of drug extrapolated to infinite time.

  From Day 1 to Day 11

• Time of Maximum Observed Plasma Concentration (Tmax) of Entrectinib

  Tmax is defined as the time (observed time point) of Cmax.

  From Day 1 to Day 11

• Apparent Terminal Elimination Half-life (t1/2) of Entrectinib

  From Day 1 to Day 11

• Apparent Oral Clearance (CL/F) of Entrectinib

  CL/F is defined as the apparent oral clearance following administration of the drug.

  From Day 1 to Day 11

• The Apparent Volume of Distribution (Vz/F) of Entrectinib

  Vz/F is defined as the apparent volume of distribution of the drug.

  From Day 1 to Day 11

• Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

  From Day 1 to Day 16

Study Arms (2)

Group A

EXPERIMENTAL

Drug: YZJ-1139 tablets; Drug: Escitalopram oxalate tablets; Drug: YZJ-1139 simulated tablets

Group B

PLACEBO COMPARATOR

Drug: Escitalopram oxalate tablets; Drug: YZJ-1139 simulated tablets

Interventions

YZJ-1139 tablets DRUG

YZJ-1139 tablets are administered orally single dose

Group A

Escitalopram oxalate tablets DRUG

•oral tablet, QD

Group A; Group B

YZJ-1139 simulated tablets DRUG

oral tablet, QD

Group A; Group B

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female subjects aged 18 to 45 years (inclusive);
• Weight ≥ 50.0 kg for males, or ≥ 45.0 kg for females, and body mass index (BMI) in the range of 19.0 \~ 28.0 kg/m2 (inclusive);
• Subjects with normal physical examination, vital signs, 12-lead ECG and laboratory tests results or abnormal but no clinical significance;
• Subjects who are in good health and have no history of serious or chronic diseases such as respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, mental system;
• Subjects of childbearing potential (including partners) have no family planning or donate sperm/eggs from 2 weeks before screening to 3 months after dosing, and voluntarily take appropriate contraceptive measures;
• Subjects who are able to understand and willing to complete the study in strict compliance with the clinical protocol and sign the informed consent form.

You may not qualify if:

• Allergic constitution, such as those with a known history of allergies to two or more drugs or foods, or those with a history of allergies to experimental drugs or excipients;
• Subjects with difficulty swallowing tablets and special dietary requirements who cannot accept a unified diet;
• Subjects who have poor peripheral venous access or cannot tolerate venous puncture or have a history of needle and blood fainting;
• Subjects who have undergone surgery within 30 days prior to screening, or plan to undergo surgery during the study;
• Individuals with a history of paroxysmal sleep disorder, obstructive sleep apnea, complex sleep behavior (such as dream walking, driving in dreams, etc.), severe unconscious hypoglycemia, stroke, epilepsy, and other psychiatric disorders (including anxiety, depression, etc.), convulsive diseases, and sudden onset of illness;
• Known to have QT prolongation or congenital QT syndrome or screening period electrocardiogram showed QTc interval (QTcF)\>450 msec in males and\>470 msec in females（QTcF= QT/(RR\^0.33)）;
• Those who are positive in any index screening of hepatitis B virus surface antigen, hepatitis C virus antibody, Treponema pallidum-specific antibody, and human immunodeficiency virus antibody;
• Subjects with a history of drug abuse, drug use within 6 months before screening, or positive drug abuse screening;
• Subjects who frequently consume alcohol within 3 months prior to screening, i.e., consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% spirits, alcohol or 150 mL of wine), or who cannot stop using any alcohol products during the study, or whose alcohol breath test result \> 0.0 mg/100 mL;
• Subjects who have donated blood or experienced massive blood loss (\> 400 mL) within 3 months prior to screening, received blood transfusions or used blood products, planned to donate blood during the trial period or within 1 month after the end of the trial;
• Subjects who have consumed excessive tea, coffee and/or caffeine-containing beverages (more than 8 cups, 1 cup ≈ 250 mL) daily during the 3 months before screening;
• Subjects smoke an average of 5 or more cigarettes per day within 3 months prior to screening, or those who cannot stop using any tobacco products during the study;
• Subjects who have participated in any clinical trial and have used clinical trial drugs or medical device within 3 months prior to screening, or plan to participate in other clinical trials during the study;
• Subjects who have received vaccination within 30 days prior to screening, or plan to receive vaccination during the study;
• Subjects who have used any drugs that inhibit or induce hepatic metabolism of drugs within 30 days prior to admission (e.g., inducers - barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; inhibitors - SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative hypnotics, verapamil, fluoroquinolones, antihistamines);

Sponsors & Collaborators

• Shanghai Haiyan Pharmaceutical Technology Co., Ltd.: lead

Study Sites (1)

The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, China

Location

MeSH Terms

Conditions

Sleep Initiation and Maintenance Disorders

Interventions

Escitalopram

Condition Hierarchy (Ancestors)

Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases; Mental Disorders

Intervention Hierarchy (Ancestors)

Propylamines; Amines; Organic Chemicals; Nitriles; Benzofurans; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Drug interaction

Study Record Dates

• First Submitted: October 31, 2024
• First Posted: November 8, 2024
• Study Start: August 31, 2024
• Primary Completion: September 18, 2024
• Study Completion: January 1, 2025
• Last Updated: November 8, 2024

Record last verified: 2024-11

Locations

CN (1)